{"ok":true,"nota":{"id":"126e7d7b666fe953","slug":"las-aprobaciones-de-medicamentos-contra-el-cancer-en-ee-uu-entre-2014--126e7d","titulo":"Las aprobaciones de medicamentos contra el cáncer en EE.UU. entre 2014 y 2025, comparadas","resumen":"Analizaron las aprobaciones de la FDA de fármacos contra el cáncer entre 2014 y 2025. Compararon tratamientos de inmunoterapia con los que no lo son, según tamaño de los ensayos, criterios de resultado y tiempo de desarrollo.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Bapodra, N., Morse, K. G., Bates, S. E., Fojo, T.","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366185v1?rss=1","imagen":"/hoy/portada/126e7d7b666fe953","tema":"salud","subtemas":["oncologia","aprobacion de medicamentos","inmunoterapia","fda","ensayos clinicos"],"entidades":["FDA","EMA"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-24T00:00:00.000Z","indexTs":"2026-10-24T17:39:23.297Z","hash":"038657cd376f44496b9a7590e43db60b37f192da29cc6f210b191b207a926c8e","tsa":{"time":"Oct 24 17:39:57 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Cuando un medicamento contra el cáncer llega a aprobarse, no siempre queda claro cuánto ayuda realmente. Este análisis muestra cómo se decidió en la última década, algo útil para leer con más criterio las noticias sobre nuevos tratamientos. Es un preprint y todavía no fue revisado por pares.","quienFirma":"medRxiv · preprints","confianza":"preprint","consulta":null},"sello":{"hash":"038657cd376f44496b9a7590e43db60b37f192da29cc6f210b191b207a926c8e","sello":"31bfeaf1f1b3b0a55602c7630b417215ebe9c7d2d85a3af1f20afcb8682e3709","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6581085,"aleatorio":"5b865f7af2191a181b92c4c4ab9fd35f643326bc2ed067db2612852f0ae4996e","tiempo":"2026-10-24T17:39:30.000Z"},"nist":{"cadena":2,"pulso":1997736,"salida":"FC410DB31A7510C007E12A13FA60BB017FD018E8D7A8F997D064784DE6DE8152F12BD532D1109184B573A519C46C35BE2929E1AD4C35C12237D4B53C3B1E21E0","tiempo":"2026-10-24T17:39:00.000Z"},"noAntes":"2026-10-24T17:39:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 24 17:39:57 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"USFDA Oncology Drug Approvals from 2014- 2025: Comparing non-immunotherapy and immunotherapy approvals, their endpoints, and their efficacy.","descripcion":"In the United States the Food and Drug Administration (FDA), and in Europe, the European Medicines Agency (EMA) are responsible for regulatory approvals of anti-cancer therapeutics. We examined regulatory approvals by both agencies in the period between 2014 and 2025 and compared immunotherapy and non-immunotherapy approvals for the treatment of cancer. We asked whether the approvals were similar in terms of trial size, endpoints, and development time. We present the data based on the FDA approvals given that the US agency has approved some therapies either rejected by or yet to be approved by the EMA. Beginning with the approval of pembrolizumab for melanoma in 2014 through early 2025 we id","pubDate":"2026-10-24","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366185v1?rss=1"},"indexado":"2026-10-24T17:39:23.297Z"}}